Elanco Announces Breakthrough Treatment for Deadly Canine Parvovirus - Seite 2
The conditional license approval—granted by the USDA to effectively and safely meet an emergency situation, limited market or special circumstance—of the first-ever targeted monoclonal antibody treatment for canine parvovirus bridges Elanco’s expertise in both therapeutics and vaccines. In the treatment efficacy study, the Canine Parvovirus Monoclonal Antibody was proven effective in decreasing mortality associated with parvovirus infection.iii Treated dogs also had significantly faster times to resolution of the most-adverse effects of parvovirus including vomitingiv, meaning that they feel better faster and get home sooner.
Prior to Elanco’s Canine Parvovirus Monoclonal Antibody, the only treatment for the highly contagious canine parvovirus was supportive therapy, which can consist of 24/7 care, multi-day hospitalization and emotional stress for the staff and pet owner with no guaranteed outcome and potentially high pet owner costs. In conjunction with its portfolio of innovative solutions, this announcement establishes Elanco’s presence in the monoclonal antibody space and reinforces its commitment to helping pets live longer, healthier lives through its portfolio of innovative solutions.
For more information, please visit: FightParvo.com.
ABOUT ELANCO
Elanco Animal Health (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we’re driven by our vision of Food and Companionship Enriching Life and our approach to sustainability, Elanco Healthy Purpose– all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com.
______________________________ |
i Venn, E.C. et al. Evaluation of an outpatient protocol in the treatment of canine parvoviral enteritis. Journal of Veterinary Emergency and Critical Care. 27(1) 2017, 52-65. doi: 10.1111/vec.12561. |
ii Elanco Animal Health. Data on File. VetSuccess Parvovirus Incidence Analysis |
iii Elanco Animal Health. Data on File. |
iv Elanco Animal Health. Data on File. |
2023 Elanco or its affiliates. PM-US-23-0232.
Lesen Sie auch
View source version on businesswire.com: https://www.businesswire.com/news/home/20230427005591/en/
The Elanco Animal Health Stock at the time of publication of the news with a raise of +2,97 % to 8,68EUR on Tradegate stock exchange (02. Mai 2023, 14:30 Uhr).